Training Example: Rebinyn – Review the Data, Give Your Score & Compare to the Real AI Evaluation

Industry Context — Common BS Fingerprints in Medical Devices, Pharma & Biotech
Generic Claims: advancing human health, breakthrough innovation, life-changing therapies, transforming patient outcomes…
Red Flags: FDA cleared used interchangeably with FDA approved, clinical claims without published study citations, breakthrough claims for incremental improvements, regulatory status implied but not specified…
Semantic Drift Patterns: homepage claims breakthrough but pipeline page shows preclinical only, FDA approved claims but only for one indication, marketed broadly, claims clinical evidence but links to poster presentations not published studies, claims global reach but regulatory approvals are single-market…
Proof Expectations: specific regulatory clearance numbers (FDA 510(k), CE, TGA), published clinical trial results with ClinicalTrials.gov registration, ISO 13485 and GMP certification details, peer-reviewed publication citations…

Rebinyn

(https://rebinyn.com) 📸 Data Snapshot: June 19, 2026

Analyze the raw signals below. How would a machine score this business’s credibility?

Here are the exact signals captured from up to six pages of the site — the same raw inputs the evaluation engine analyzed. They are grouped by signal type so you can weigh each the way the machine does.

🏗️ Semantic Structure — heading hierarchy & page identity (Info Density · Commodity Fingerprint)
HOMEPAGE Take Control of Hemophilia B | Rebinyn® Coagulation Factor IX (Recombinant), GlycoPEGylated (https://rebinyn.com)
Title

Take Control of Hemophilia B | Rebinyn® Coagulation Factor IX (Recombinant), GlycoPEGylated

Meta

Rebinyn® is an injectable treatment used to replace clotting Factor IX in people with hemophilia B. It can be used as routine prophylaxis to reduce the number of bleeding episodes. Read important safety & prescribing info.

H1 APPROVED
H2 Rebinyn®
H2 Be ready for the unexpected
H2 Be ready for the unexpected
H2 SIMPLE ONCE-WEEKLY DOSING FOR ROUTINE PROPHYLAXIS:
H2 MAINTAINING FACTOR LEVELS BETWEEN DOSES
H2 REBINYN® HELPS YOU ACHIEVE HIGH FACTOR LEVELS SO YOU CAN BE READY FOR THE UNEXPECTEDc
H2 STAY IN THE KNOW.
H2 STAY IN THE KNOW.
H2 Selected Important Safety Information
H2 Indications and Usage
H2 Important Safety Information
H3 (Coagulation Factor IX [Recombinant], GlycoPEGylated)
H3 To prevent or reduce the number of bleeding episodes in people with hemophilia B
H3 Once-weekly Rebinyn® helps you keep Factor 9 levels higher for longer.a
H3 To prevent or reduce the number of bleeding episodes in people with hemophilia B
H3 Once-weekly Rebinyn® helpsyou keep Factor 9 levels higher for longer.a
H3 The World Federation of Hemophilia (WFH)b says an extended half-life prophylaxis can allow individuals to keep Factor 9 levels in the non-hemophilia range (greater than 40%) for a significant amount of time.
H3 The World Federation of Hemophilia (WFH)b says an extended half-life prophylaxis can allow individuals to keep Factor 9 levels in the non-hemophilia range (greater than 40%) for a significant amount of time.
H3 Previously treated adults achieved Factor 9 levels in the non-hemophilia range (greater than 40%)c
H3 IN ADULTS THE HALF-LIFEe WAS
H3 IN ADOLESCENTS THEHALF-LIFEe WAS
H3 IN ADULTS THE HALF-LIFEe WAS
H3 IN ADOLESCENTS THEHALF-LIFEe WAS
H3 Clinical trials over
H3 showed 0 inhibitors and 0 blood clots in previously treated patients.
H3 The formation of inhibitors (neutralizing antibodies) to Factor 9 has occurred following Rebinyn®. Common adverse reactions (incidence ≥1%) in PUPs reported in clinical trials for Rebinyn® included Factor 9 inhibitors. The use of Factor 9-containing products has been associated with blood clots.
H3 WE'RE HERE TO HELP
H3 WE'RE HERE TO HELP
H3 Sign up to get the latest updates on Rebinyn®
H3 Sign up to get the latest updates on Rebinyn®
NAV_HEADER_HEADING_REPEATED_BODY_FOOTER Contact a Novo Nordisk Representative | Rebinyn® Coagulation Factor IX (Recombinant), GlycoPEGylated (https://rebinyn.com/help/contact-reps.html)
Title

Contact a Novo Nordisk Representative | Rebinyn® Coagulation Factor IX (Recombinant), GlycoPEGylated

Meta

Novo Nordisk representatives are a great source for information and support. Reps can also connect you to a variety of community resources and product support to help you manage your hemophilia B. Read important safety & prescribing info.

H2 Rebinyn®
H2 STAY IN THE KNOW
H2 STAY IN THE KNOW
H2 Selected Important Safety Information
H2 Indications and Usage
H2 Important Safety Information
H3 (Coagulation Factor IX [Recombinant], GlycoPEGylated)
H3 CONTACT A NOVO NORDISK RARE BLOOD COMMUNITY LIAISON (RBCL)
H3 Enter your zip code to find your RBCL.
H3 Sign up to get the latest updates from Rebinyn®
H3 Sign up to get the latest updates from Rebinyn®
NAV_HEADER_HEADING_REPEATED_BODY_FOOTER Safety Considerations | Rebinyn® Coagulation Factor IX (Recombinant), GlycoPEGylated (https://rebinyn.com/safety-considerations.html)
Title

Safety Considerations | Rebinyn® Coagulation Factor IX (Recombinant), GlycoPEGylated

Meta

Stay informed on the safety considerations of Rebinyn®, and its manufacturing. Learn about side effects, studies, and safety profile (inhibitors & blood clots). Read important safety & prescribing info.

H1 DESIGNED FOR SAFETY
H2 Rebinyn®
H2 The safety of Rebinyn® has been established in 5 clinical trials over 13 years.
H2 OVER 13 YEARS OF CLINICAL TRIAL SAFETY DATA
H2 IT'S EASY TO GET STARTED
H2 HOW IT EXTENDS HALF-LIFE
H2 STAY IN THE KNOW
H2 STAY IN THE KNOW
H2 Selected Important Safety Information
H2 Indications and Usage
H2 Important Safety Information
H3 (Coagulation Factor IX [Recombinant], GlycoPEGylated)
H3 previously treated patients
H3 exposure days in previously treated patientsa
H3 patient-years of experience in previously treated patientsb
H3 inhibitors or blood clots in previously treated patients
H3 You may be at an increased risk of forming blood clots in your body, especially if you have risk factors for developing blood clots. Call your healthcare provider if you have chest pain, difficulty breathing, leg tenderness, or swelling.
H3 Your body can also make antibodies called “inhibitors” against Factor 9, including Rebinyn®, which may stop Rebinyn® from working properly. Your healthcare provider may need to test your blood for inhibitors from time to time. Formation of inhibitors to Factor 9 has occurred following Rebinyn®.
H3 Common side effects in previously untreated patients include Factor 9 inhibitors.
H3 MANUFACTURED WITH SAFETY IN MIND
H3 MANUFACTURED WITH SAFETY IN MIND
H3 WHAT ABOUT SIDE EFFECTS?
H3 WHO SHOULD NOT TAKE REBINYN®?
H3 Sign up to get the latest updates from Rebinyn®
H3 Sign up to get the latest updates from Rebinyn®
NAV_HEADER_HEADING_REPEATED_BODY_FOOTER Elevate Factor Levels | Rebinyn® Coagulation Factor IX (Recombinant), GlycoPEGylated (https://rebinyn.com/why/high-factor-levels.html)
Title

Elevate Factor Levels | Rebinyn® Coagulation Factor IX (Recombinant), GlycoPEGylated

Meta

See how Rebinyn® elevates coagulation factor levels for those with Hemophilia B. Learn about fixed dosing – no adjustments for minor / moderate bleeds. Read important safety & prescribing info.

H1 BE READY WITH REBINYN®
H2 Rebinyn®
H2 Rebinyn® helps you achieve higher factor levels so you can be ready for the unexpected.a
H2 PREVIOUSLY TREATED ADULTS ACHIEVED FACTOR 9 LEVELS IN THE NON-HEMOPHILIA RANGE (GREATER THAN 40%)a
H2 HIGH LEVELS WITH REBINYN® CAN HELP KIDS BE READY FOR THE UNEXPECTED
H2 DID YOU KNOW?
H2 Half-life is the time it takes for the level of factor in the blood to fall by half (50%).
H2 INTERESTED IN TRYING REBINYN®?
H2 STAY IN THE KNOW
H2 STAY IN THE KNOW
H2 Selected Important Safety Information
H2 Indications and Usage
H2 Important Safety Information
H3 (Coagulation Factor IX [Recombinant], GlycoPEGylated)
H3 IN ADULTS, THEHALF-LIFEc WAS
H3 IN ADOLESCENTS, THE HALF-LIFEc WAS
H3 IN ADULTS, THEHALF-LIFEc WAS
H3 IN ADOLESCENTS, THE HALF-LIFEc WAS
H3 MAINTAINING FACTOR LEVELS BETWEEN DOSES
H3 MAINTAINING FACTOR LEVELS BETWEEN DOSES
H3 HIGH FACTOR 9 LEVELS IN CHILDREN 12 YEARS OR YOUNGER
H3 PREVENT BLEEDS WITH REBINYN®
H3 CONSIDERING A SWITCH?
H3 Sign up to get the latest updates from Rebinyn®
H3 Sign up to get the latest updates from Rebinyn®
📝 The Narrative — clean text per page (Info Density · Semantic Coherence)
HOMEPAGE (https://rebinyn.com) Take Control of Hemophilia B | Rebinyn® Coagulation Factor IX (Recombinant), GlycoPEGylated
[H2]
Selected Important Safety Information

What is the most important information I need to know about Rebinyn®?
Do not attempt to do an infusion yourself unless you have been taught how by your healthcare provider or hemophilia treatment center. Carefully follow your healthcare provider’s instructions regarding the dose and schedule for infusing Rebinyn®.

Who should not use Rebinyn®?
Do not use Rebinyn® if you:
are allergic to Factor IX or any of the other ingredients of Rebinyn®.
are allergic to hamster proteins.

[H2]
Indications and Usage

What is Rebinyn®, Coagulation Factor IX (Recombinant), GlycoPEGylated?
Rebinyn® is an injectable medicine used to replace clotting Factor IX that is missing in patients with hemophilia B. Rebinyn® is used to treat, prevent, or reduce the frequency (number) of bleeding episodes in people with hemophilia B. Your healthcare provider may give you Rebinyn® when you have surgery. Rebinyn® is not used for immune tolerance therapy.

[H2]
Important Safety Information

What is the most important information I need to know about Rebinyn®?
Do not attempt to do an infusion yourself unless you have been taught how by your healthcare provider or hemophilia treatment center. Carefully follow your healthcare provider’s instructions regarding the dose and schedule for infusing Rebinyn®.

Who should not use Rebinyn®?
Do not use Rebinyn® if you:
are allergic to Factor IX or any of the other ingredients of Rebinyn®.
are allergic to hamster proteins.

What should I tell my healthcare provider before using Rebinyn®?
Tell your healthcare provider if you:

have or have had any medical conditions.
take any medicines, including non-prescription medicines and dietary supplements.
are nursing, pregnant, or plan to become pregnant.
have been told you have inhibitors to Factor IX.

How should I use Rebinyn®?
Rebinyn® is given as an infusion into the vein.
Call your healthcare provider right away if your bleeding does not stop after taking Rebinyn®.
Do not stop using Rebinyn® without consulting your healthcare provider.

What are the possible side effects of Rebinyn®?

Common side effects include infusion site reaction (bruising, bleeding, swelling, pain, or redness), itching, and rash.
Your body can also make antibodies called “inhibitors” against Factor IX, including Rebinyn®, which may stop Rebinyn® from working properly. Your healthcare provider may need to test your blood for inhibitors from time to time.
Call your healthcare provider right away or get emergency treatment right away if you get, for example, any of the following signs of an allergic reaction: hives, chest tightness, wheezing, difficulty breathing, and/or swelling of the face.
You may be at an increased risk of forming blood clots in your body, especially if you have risk factors for developing blood clots. Call your healthcare provider if you have chest pain, difficulty breathing, leg tenderness, or swelling.
Animals given repeat doses of Rebinyn® showed Polyethylene Glycol (PEG) in certain cells in the brain. The potential human implications of these animal tests are unknown.

Please click here for Rebinyn® Prescribing Information.
Rebinyn® is a prescription medication.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
3455 chars
SUB-PAGE (https://rebinyn.com/help/contact-reps.html) Contact a Novo Nordisk Representative | Rebinyn® Coagulation Factor IX (Recombinant), GlycoPEGylated
[H2]
Selected Important Safety Information

What is the most important information I need to know about Rebinyn®?
Do not attempt to do an infusion yourself unless you have been taught how by your healthcare provider or hemophilia treatment center. Carefully follow your healthcare provider’s instructions regarding the dose and schedule for infusing Rebinyn®.

Who should not use Rebinyn®?
Do not use Rebinyn® if you:
are allergic to Factor IX or any of the other ingredients of Rebinyn®.
are allergic to hamster proteins.

[H2]
Indications and Usage

What is Rebinyn®, Coagulation Factor IX (Recombinant), GlycoPEGylated?
Rebinyn® is an injectable medicine used to replace clotting Factor IX that is missing in patients with hemophilia B. Rebinyn® is used to treat, prevent, or reduce the frequency (number) of bleeding episodes in people with hemophilia B. Your healthcare provider may give you Rebinyn® when you have surgery. Rebinyn® is not used for immune tolerance therapy.

[H2]
Important Safety Information

What is the most important information I need to know about Rebinyn®?
Do not attempt to do an infusion yourself unless you have been taught how by your healthcare provider or hemophilia treatment center. Carefully follow your healthcare provider’s instructions regarding the dose and schedule for infusing Rebinyn®.

Who should not use Rebinyn®?
Do not use Rebinyn® if you:
are allergic to Factor IX or any of the other ingredients of Rebinyn®.
are allergic to hamster proteins.

What should I tell my healthcare provider before using Rebinyn®?
Tell your healthcare provider if you:

have or have had any medical conditions.
take any medicines, including non-prescription medicines and dietary supplements.
are nursing, pregnant, or plan to become pregnant.
have been told you have inhibitors to Factor IX.

How should I use Rebinyn®?
Rebinyn® is given as an infusion into the vein.
Call your healthcare provider right away if your bleeding does not stop after taking Rebinyn®.
Do not stop using Rebinyn® without consulting your healthcare provider.

What are the possible side effects of Rebinyn®?

Common side effects include infusion site reaction (bruising, bleeding, swelling, pain, or redness), itching, and rash.
Your body can also make antibodies called “inhibitors” against Factor IX, including Rebinyn®, which may stop Rebinyn® from working properly. Your healthcare provider may need to test your blood for inhibitors from time to time.
Call your healthcare provider right away or get emergency treatment right away if you get, for example, any of the following signs of an allergic reaction: hives, chest tightness, wheezing, difficulty breathing, and/or swelling of the face.
You may be at an increased risk of forming blood clots in your body, especially if you have risk factors for developing blood clots. Call your healthcare provider if you have chest pain, difficulty breathing, leg tenderness, or swelling.
Animals given repeat doses of Rebinyn® showed Polyethylene Glycol (PEG) in certain cells in the brain. The potential human implications of these animal tests are unknown.

Please click here for Rebinyn® Prescribing Information.
Rebinyn® is a prescription medication.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
3455 chars
SUB-PAGE (https://rebinyn.com/safety-considerations.html) Safety Considerations | Rebinyn® Coagulation Factor IX (Recombinant), GlycoPEGylated
[H2]
Selected Important Safety Information

What is the most important information I need to know about Rebinyn®?
Do not attempt to do an infusion yourself unless you have been taught how by your healthcare provider or hemophilia treatment center. Carefully follow your healthcare provider’s instructions regarding the dose and schedule for infusing Rebinyn®.

Who should not use Rebinyn®?
Do not use Rebinyn® if you:
are allergic to Factor IX or any of the other ingredients of Rebinyn®.
are allergic to hamster proteins.

[H2]
Indications and Usage

What is Rebinyn®, Coagulation Factor IX (Recombinant), GlycoPEGylated?
Rebinyn® is an injectable medicine used to replace clotting Factor IX that is missing in patients with hemophilia B. Rebinyn® is used to treat, prevent, or reduce the frequency (number) of bleeding episodes in people with hemophilia B. Your healthcare provider may give you Rebinyn® when you have surgery. Rebinyn® is not used for immune tolerance therapy.

[H2]
Important Safety Information

What is the most important information I need to know about Rebinyn®?
Do not attempt to do an infusion yourself unless you have been taught how by your healthcare provider or hemophilia treatment center. Carefully follow your healthcare provider’s instructions regarding the dose and schedule for infusing Rebinyn®.

Who should not use Rebinyn®?
Do not use Rebinyn® if you:
are allergic to Factor IX or any of the other ingredients of Rebinyn®.
are allergic to hamster proteins.

What should I tell my healthcare provider before using Rebinyn®?
Tell your healthcare provider if you:

have or have had any medical conditions.
take any medicines, including non-prescription medicines and dietary supplements.
are nursing, pregnant, or plan to become pregnant.
have been told you have inhibitors to Factor IX.

How should I use Rebinyn®?
Rebinyn® is given as an infusion into the vein.
Call your healthcare provider right away if your bleeding does not stop after taking Rebinyn®.
Do not stop using Rebinyn® without consulting your healthcare provider.

What are the possible side effects of Rebinyn®?

Common side effects include infusion site reaction (bruising, bleeding, swelling, pain, or redness), itching, and rash.
Your body can also make antibodies called “inhibitors” against Factor IX, including Rebinyn®, which may stop Rebinyn® from working properly. Your healthcare provider may need to test your blood for inhibitors from time to time.
Call your healthcare provider right away or get emergency treatment right away if you get, for example, any of the following signs of an allergic reaction: hives, chest tightness, wheezing, difficulty breathing, and/or swelling of the face.
You may be at an increased risk of forming blood clots in your body, especially if you have risk factors for developing blood clots. Call your healthcare provider if you have chest pain, difficulty breathing, leg tenderness, or swelling.
Animals given repeat doses of Rebinyn® showed Polyethylene Glycol (PEG) in certain cells in the brain. The potential human implications of these animal tests are unknown.

Please click here for Rebinyn® Prescribing Information.
Rebinyn® is a prescription medication.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
3455 chars
SUB-PAGE (https://rebinyn.com/why/high-factor-levels.html) Elevate Factor Levels | Rebinyn® Coagulation Factor IX (Recombinant), GlycoPEGylated
[H2]
Selected Important Safety Information

What is the most important information I need to know about Rebinyn®?
Do not attempt to do an infusion yourself unless you have been taught how by your healthcare provider or hemophilia treatment center. Carefully follow your healthcare provider’s instructions regarding the dose and schedule for infusing Rebinyn®.

Who should not use Rebinyn®?
Do not use Rebinyn® if you:
are allergic to Factor IX or any of the other ingredients of Rebinyn®.
are allergic to hamster proteins.

[H2]
Indications and Usage

What is Rebinyn®, Coagulation Factor IX (Recombinant), GlycoPEGylated?
Rebinyn® is an injectable medicine used to replace clotting Factor IX that is missing in patients with hemophilia B. Rebinyn® is used to treat, prevent, or reduce the frequency (number) of bleeding episodes in people with hemophilia B. Your healthcare provider may give you Rebinyn® when you have surgery. Rebinyn® is not used for immune tolerance therapy.

[H2]
Important Safety Information

What is the most important information I need to know about Rebinyn®?
Do not attempt to do an infusion yourself unless you have been taught how by your healthcare provider or hemophilia treatment center. Carefully follow your healthcare provider’s instructions regarding the dose and schedule for infusing Rebinyn®.

Who should not use Rebinyn®?
Do not use Rebinyn® if you:
are allergic to Factor IX or any of the other ingredients of Rebinyn®.
are allergic to hamster proteins.

What should I tell my healthcare provider before using Rebinyn®?
Tell your healthcare provider if you:

have or have had any medical conditions.
take any medicines, including non-prescription medicines and dietary supplements.
are nursing, pregnant, or plan to become pregnant.
have been told you have inhibitors to Factor IX.

How should I use Rebinyn®?
Rebinyn® is given as an infusion into the vein.
Call your healthcare provider right away if your bleeding does not stop after taking Rebinyn®.
Do not stop using Rebinyn® without consulting your healthcare provider.

What are the possible side effects of Rebinyn®?

Common side effects include infusion site reaction (bruising, bleeding, swelling, pain, or redness), itching, and rash.
Your body can also make antibodies called “inhibitors” against Factor IX, including Rebinyn®, which may stop Rebinyn® from working properly. Your healthcare provider may need to test your blood for inhibitors from time to time.
Call your healthcare provider right away or get emergency treatment right away if you get, for example, any of the following signs of an allergic reaction: hives, chest tightness, wheezing, difficulty breathing, and/or swelling of the face.
You may be at an increased risk of forming blood clots in your body, especially if you have risk factors for developing blood clots. Call your healthcare provider if you have chest pain, difficulty breathing, leg tenderness, or swelling.
Animals given repeat doses of Rebinyn® showed Polyethylene Glycol (PEG) in certain cells in the brain. The potential human implications of these animal tests are unknown.

Please click here for Rebinyn® Prescribing Information.
Rebinyn® is a prescription medication.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
3455 chars
🛡️ Trust Signals — reviews, proof links, trust-theatre flag (Trust & Proof)
2Review mentions (all pages)
0External proof links (all pages)
PageReviewsProof links
/ (home) 1 0
/help/contact-reps.html 0 0
/safety-considerations.html 0 0
/why/high-factor-levels.html 1 0
🔗 Identity & Technical Layer — schema JSON-LD: identity chains, entity gaps (Identity & Authority)
Homepage — no schema detected (entity gap)
/help/contact-reps.html — no schema detected (entity gap)
/safety-considerations.html — no schema detected (entity gap)
/why/high-factor-levels.html — no schema detected (entity gap)

Your Diagnosis

Before revealing the machine’s verdict, predict the BS score for each signal. Higher = more BS (more fluff, less verifiable substance). Drag each slider, then submit to compare your judgment against the engine.

Information Density 0 / 30
Read the Narrative & headings: do hard facts (prices, dates, numbers) outweigh fluff power-words?
Semantic Coherence 0 / 20
Compare the homepage promise against the sub-page reality. Do they hold the same line?
Trust & Proof 0 / 20
Weigh review mentions against actual external proof links. Claims without verification = theatre.
Commodity Fingerprint 0 / 15
Check headings & narrative against the industry clichés in the setup above.
Identity & Authority 0 / 15
Inspect the schema: is there real Organization/Person identity with sameAs links, or gaps?
Your predicted BS score 0 / 100
💡 Stuck? Reveal the heuristic lens — how the deterministic page-auditor reads each signal (no AI, pure pattern rules)

These are the structural rules a local, deterministic auditor applies — the same lens you can use to judge each signal. They describe what to look for, not this company’s result.

Information Density

Classify each sentence as substantive or hollow. Grounding markers — numbers, currencies, dates, technical units, named entities — outweigh marketing adjectives. When fluff sits right next to hard evidence, the fluff is forgiven.

Semantic Alignment

Pull the main entities out of the H1, then check whether they actually recur through the body. A page that announces one thing and then talks about another drifts. Headings with no real sentences underneath read as pseudo-substance.

Trust & Proof

Count trust words (review, testimonial, rating, verified) against real outbound proof links (Google, Trustpilot, Clutch, G2, Yelp). Lots of trust language with zero verification links is trust theatre. Unlinked logo galleries count against it.

Commodity Fingerprint

Look at how much sentence length varies. Natural writing varies its rhythm; templated or mass-produced copy is statistically uniform. Very low variation reads as commodity content — unless unique named entities break the pattern.

Identity & Authority

Inspect the JSON-LD. Is there an Organization or Person schema, and does it carry sameAs links to real external profiles (LinkedIn, socials)? Missing schema or no identity declaration signals an anonymous entity.

Want to apply this lens yourself? The free BS Indicator Chrome extension runs these heuristic checks live on any page. Bear in mind it is a single-page, deterministic tool — it relies only on pattern rules for the page in front of it and does not perform the cross-page semantic correlation this audit uses, so its readout is a starting lens, not the full verdict.

B
BS Level
Medical Devices, Pharma & Biotech
40.7 Avg BS

Based on 784 businesses audited.

BS Detector

Medical Devices, Pharma & Biotech BS: Rebinyn (rebinyn.com)

https://rebinyn.com 📍 Industry: Medical Devices, Pharma & Biotech
45 BS / 100

Rebinyn delivers a high-substance clinical message trapped in a low-substance marketing shell. While the clinical data is robust and specific, the site’s technical implementation—specifically the lack of schema and the presence of unverified trust signals—creates a moderate BS profile typical of large pharma products prioritizing compliance over digital transparency.

Info Density Power-words vs. Substance ratio.
10
33% BS
Semantic Coherence Homepage promise vs. Sub-page reality.
4
20% BS
Trust & Proof Verifiable evidence vs. Trust Theatre.
13
65% BS
Commodity Fingerprint Detection of industry clichés/templates.
8
53% BS
Identity & Authority Expert verifiability & Schema depth.
10
67% BS

Immediately implement Organization and MedicalWebPage schema to anchor the brand’s authority and verify clinical claims. Replace the repetitive ‘Stay in the Know’ H2 tags with descriptive, substance-led headers that highlight specific trial findings. Provide direct outbound links to the specific peer-reviewed studies or the ClinicalTrials.gov registry entries to move from trust theatre to verified proof. Reduce the frequency of the ‘unexpected’ tagline in favor of more granular pharmacokinetic data in the primary heading hierarchy.

The content strictly adheres to the Medical/Pharma category, characterized by extensive mandatory Safety Information, regulatory indications, and clinical trial data references. The presence of terms like Coagulation Factor IX (Recombinant) and GlycoPEGylated confirms a high-fidelity industry match.

“The score of 45 is primarily driven by the total lack of structured data (Step 5) and the detection of unverified trust signals (Step 3). While the information density is high regarding clinical facts, the heavy repetition of marketing taglines (Step 1) prevents a lower BS score.”

Verified Analysis Date: June 19, 2026 © 1EuroSEO Independent Evaluator — Non-Sponsored Result
Brand AI Reputation